Articles On Orthocell (ASX:OCC)

Highlights ASX 300 showcases top movers with significant percentage changes across sectors. Consumer Discretionary and Telecommunications drive market gains amid stable sentiment. ASX mining and energy stocks experience mixed outcomes...

Highlights Web Travel Group WEB shares rise 13.48% following strong TTV growth. Pinnacle Investment Management PNI declines after announcing $25M SPP. ASX rebounds, with all sectors closing in positive territory. The Australian sh...

ASX rises on rally across the board Israel and Hezbollah agree to 60-day ceasefire City Chic tumbles after downbeat update   The Aussie share market enjoyed a solid ride on Wednesday, driven by a broad rally as optimism from Wall Street’s...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) medical device sales in Singapore on the appointment of an exclusive distributor. It...

Orthocell (ASX:OCC) has appointed Device Technologies Asia (DVT Asia) as the exclusive distributor of its nerve repair device, Remplir, in Singapore. This marks the product's first major international expansion beyond Australia and New Zeal...

Orthocell appoints Device Technologies Asia as exclusive distributor of nerve repair product Remplir in Singapore Device Technologies has been credited with driving rapid sales of Remplir in Australia and New Zealand Orthocell said market...

Nerve-repair company Renerve is set to make its ASX debut today Renerve is developing products for repair and replacement of damaged peripheral nerves It becomes only the second nerve-repair company on the ASX, after Orthocell   When Rene...

Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chairman John Van Der Wielen to get the short end of the long story on the company’s latest news. The regenerative medicine company has appointed two US-based executives to drive t...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Orthocell (ASX:OCC) has secured $17m in a recent capital raising initiative, aimed at funding the US launch of its flagship Remplir device. The funds will also support expansion into Singapore, Southeast Asia, and Europe, and be allocated t...

Orthocell (ASX:OCC) has announced its receipt of commitments for $17M in funding via placement to bankroll the US launch of Remplir. Remplir is a skin-like, collagen-based warp used in specific wound repairs with a view towards patient...

ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble   Aussie shares swung to a flattish close today after earlier losses...

The nerve-repair company’s shares have been on a tear after a series of positive regulatory and operating updates.

Highlights   ASX200 index falls 1.66% in its worst day in seven weeks.   Health Care sector takes the largest hit, down 2.4%.   Wisetech bounces back 2.84% after litigation settlement. The ASX200 experienced a significant drop of...

The ASX200 closed down 1.66% at 8,205 points in its worst day in seven weeks. The local bourse shed some of the gains from recent weeks as investors took profits and re-evaluated their portfolios. Health Care suffered the biggest loss...

EBR has developed the WiSE Cardiac Resynchronization Therapy (CRT) system, the world’s first leadless pacing system for heart failure Trytamine Therapeutics is pioneering a precision approach to psychedelics, targeting precise drug blood l...

Stockhead’s Sarah Hughan sits down with Orthocell’s (ASX:OCC) CEO and MD Paul Anderson to get the short end of the long story on the company’s latest news. The company has received regulatory approval from the Health Sciences Authority in S...

  Singapore’s medical regulator this week approved Orthocell’s leading nerve-repair device Remplir Remplir shows great promise in restoring function for paraplegics and quadriplegics Orthocell estimates the potential global market at US$33...

Shares in regenerative medicine company Orthocell soared after the company received regulatory approval for its nerve repair product in Singapore.

Highlights ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell as China shifted focus from construction to consumer confidence. Health Care sector gained 0.75%, while Materials dropped 1.75%. The ASX200 index closed 0.3...

The ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell from US$114/tn to US$108/tn in Singapore on news the Chinese government’s stimulus will focus more on boosting domestic spending. Instead of driving new construction,...

West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences Authority in Singapore to commence sales of its nerve repair product, Remplir. It’s the first international ap...

Orthocell gains regulatory approval from Singapore’s Health Sciences Authority for its nerve repair product Remplir It is the first major international approval for Remplir outside of Australia and New Zealand Orthocell said Singapore was...

Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow   It’s not th...

Orthocell achieves a second consecutive quarter of record revenue, reporting $2.03m in Q1 FY25 Revenue is up 7.82% on $1.88m achieved in Q4 FY24, showing traction with growing sales of Striate+ and Remplir Company said FDA approval of Rem...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...

Mesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to Somnomed: ‘do you want the good news or bad news first?’ Neurotech mulls its US options after FDA’s orphan drug decision Orthocell says reve...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Southeast Asia presents growth for ASX health stocks with rising aging population and growing middle class EZZ has started selling EAORON branded products in Vietnam and signed Australian Open sponsorship deal  Recce has signed a MoU with...

The ASX200 closed up 0.39% at 8,013 points. The bank stocks rallied leading the index higher, but Energy and mining stocks slumped in the wake of falling commodity prices. Financials was the best performing sector, up 1.45%, followed...

WA regenerative medicine company Orthocell has started selling its dental bone repair product in Canada — a market estimated to worth to be about $60 million.

The ASX200 has been up around 0.5% at 8,025 points. Bank stocks have surged and dragged the market higher with the big 4 all outperforming and dragging the bourse higher. In commodities, the gold price is fetching more than US$2500 an...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Fraser Palamara explains why the Canadian market is so important for Aussie pharmaceutical Orthocell. Tune in to get the latest. While Or...

Orthocell (ASX:OCC) has confirmed it’s sold its first units of collagen-based bone repair product Striate+ in Canada through distro partner BioHorizons. The move effectively represents a further expansion for the company into another we...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chair John Van Der Wielen to get the short end of the long story on the company’s latest news. Regenerative medicine company Orthocell is further expanding the sales of its product...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Several ASX healthcare companies are proudly manufacturing products in Australia  Polynovo, Optiscan and Trajan Group all have manufacturing facilities in Melbourne Orthocell says government funding can boost manufacturing capabilities of...

Western Australia wanting to diversity beyond resources and become a global leader in health and medical life sciences Cook Government to invest $16m into driving a connected and innovative ecosystem for WA’s health and medical research se...

The 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on new companies, diagnostics and those following a new direction Trends in healthcare and biotech sector a focus as investor sentiment improve...

Shares in WA regenerative medicine company Orthocell are up after it received regulatory approval to start selling its dental bone repair product in Canada.

The ASX200 had a strong day closing up 0.93%. All sectors closed in the green with top performer Real Estate jumping 1.5%,  followed closely by IT and Healthcare. In this bulletin, we’ll discuss Renascor, Telix Pharmaceuticals, Orthoc...

ASX 200 punches it, record highs back in view  11 of 11 sectors higher, like a well-oiled machine  Great day for small caps, goldies and Augustus Minerals Local markets surged this morning after yet another record-breaking night for Wa...

  Orthocell receives regulatory approval to sell dental guided bone regeneration product Striate+ in Canada Approval complements existing approvals for Striate+ in other key markets including the US Orthocell’s distribution partner Bio Hor...

ASX 200 closes 0.16pc lower after modest rally from morning lows  Six of 11 sectors lower, after rate-sensitive sectors improve after lunch  Killi Resources surges again with a late surge to dethrone Infini   Local markets have trimmed...

ASX 200 rises strongly on Tuesday, closes up +0.86pc  All 11 sectors in the green, like Kermit on a golf course  Top small cap was Killi Resources with a bumper +83.7pc surge   Local markets jumped on Tuesday, erasing all of Monday’s l...

  Special Report: Dropping milestone numbers this week is the Perth-based regenerative medtech Orthocell, for which record quarterly and full year revenue has been driven by a huge uptick in demand across the company’s flagship healing solu...

Orthocell (ASX:OCC) shares jumped close to 5% heading into afternoon trade as the company flagged record yearly revenues. The company sells two keystone products – Striate+ and Remplir respectively – both aimed at regenerating bones and...